Skip to content

Bristol-Myers, Calithera expand cancer collaboration

May 19, 2017

Bristol-Myers Squibb (NYSE:BMY) and Calithera Biosciences (NASDAQ:CALA) expand their cancer collaboration assessing Opdivo (nivolumab) and CB-839. They plan to evaluate the combination in non-small cell lung cancer (NSCLC) and melanoma. A clinical trial in clear cell renal cell carcinoma is already underway.

CB-839 is an orally administered inhibitor of an enzyme called glutaminase. It is designed to starve tumor cells of a protein called glutamine, a key nutrient. The rationale is that it may enhance the effects of checkpoint inhibitors and may reverse tumor resistance to checkpoint inhibitors by altering the immune-suppressive microenvironment and promoting an anti-tumor immune response. Opdivo is a PD-1 immune checkpoint inhibitor designed to overcome immune suppression.

http://bit.ly/2q2vmHW

Advertisements

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: